Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 4, 2004, Pages 399-404

  Janssen, Marcel ^a   Frielink, Cathelijne ^a   Dijkgraaf, Ingrid ^a   Oyen, Wim ^a   Edwards, D Scott ^b   Liu, Shuang ^b   Rajopadhye, Milind ^b   Massuger, Leon ^a   Corstens, Frans ^a   Boerman, Otto ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

v 3 integrin; Dose fractionation; RGD peptides; Tumor targeting

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ARGINYLGLYCYLASPARTIC ACID; INDIUM 111; RADIOISOTOPE; VITRONECTIN RECEPTOR; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA RADIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOTHELIUM CELL; FEMALE; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; DOSE FRACTIONATION; FEMALE; HUMANS; INDIUM RADIOISOTOPES; INTEGRIN ALPHAVBETA3; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; OVARIAN NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 4644282621     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2004.19.399     Document Type: Article

References (19)

1. Cheresh DA. Integrins: Structure, function and biological properties. Adv Mol Cell Biol 1993;6:225.
2. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer 1996;32A:2423.
3. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89:1870.
4. Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castelman's disease. J Pathol 1997;183:44.
5. PerezAtayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27.
7. Haubner R, Wester HJ, Reuning U, et al. Radiolabeled alpha(v)beta(3) integrin antagonists: A new class of tracers for tumor targeting. J. Nucl Med 1999;40:1061.
8. Haubner R, Wester H-J, Burkhart F, et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326.
9. Van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000;90:186.
10. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha-v-beta-3 integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146.
11. Janssen ML, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 2002;17:641.
12. 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjugate Chem 2001;12:559.
13. 111In-RP686 and efficacy in dogs. Cancer Res 2001;42:94.
14. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 2002;94:1332.
15. O'Donoghue JA, Sgouros G, Divgi CR, et al. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 2000;41:538.
16. Shen S, Duan J, Meredith RF, et al. Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer 2002;94(4[suppl]): 1264.
17. 131I-labeled monoclonal antibody CC49. Cancer Res 1995;55(23[suppl]):5881S.
18. 125I-labeled antibody at experimental radioimmunotargeting. Cancer 1997;80(12[suppl]):2510.
19. 131I-labeled multivalent CC49 single-chain fvs. Clin Cancer Res 2001;7:175.